These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7528080)

  • 1. Serum levels of c-erbB-2 protein in digestive diseases.
    Motoo Y; Sawabu N; Yamaguchi Y; Mouri I; Yamakawa O; Watanabe H; Ohta H; Okai T; Makino H
    J Gastroenterol; 1994 Oct; 29(5):616-20. PubMed ID: 7528080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sialyl-Tn antigen levels in patients with digestive cancers.
    Motoo Y; Kawakami H; Watanabe H; Satomura Y; Ohta H; Okai T; Makino H; Toya D; Sawabu N
    Oncology; 1991; 48(4):321-6. PubMed ID: 1891175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers].
    Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Okai T; Mai M; Hattori N; Akiyama T; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):119-26. PubMed ID: 3541791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour marker CA 125 in patients with digestive tract malignancies.
    Haglund C; Kuusela P; Roberts P; Jalanko H
    Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases.
    Molina R; Jo J; Filella X; Bruix J; Castells A; Hague M; Ballesta AM
    Tumour Biol; 1997; 18(3):188-96. PubMed ID: 9143415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers.
    Motoo Y; Satomura Y; Mouri I; Mouri H; Ohtsubo K; Sakai J; Fujii T; Taga H; Yamaguchi Y; Watanabe H; Okai T; Sawabu N
    Dig Dis Sci; 1999 Jun; 44(6):1142-7. PubMed ID: 10389686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum c-erbB-2 in breast cancer patients.
    Watanabe N; Miyamoto M; Tokuda Y; Kubota M; Ando Y; Tajima T; Mitomi T
    Acta Oncol; 1994; 33(8):901-4. PubMed ID: 7818922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas.
    Hedström J; Haglund C; Haapiainen R; Stenman UH
    Int J Cancer; 1996 May; 66(3):326-31. PubMed ID: 8621252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
    Ishii M
    Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken')].
    Sugano K; Kawai T; Ishii M; Koyama H; Kitajima M; Kasumi F; Demura R; Nakayama T; Okabe H; Mori S
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1245-53. PubMed ID: 7913312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
    Kuusela P; Haglund C; Roberts PJ
    Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP.
    Perng CL; Lin HJ; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Aug; 54(2):82-6. PubMed ID: 7525029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum ferritin levels as a marker of various digestive diseases (author's transl)].
    Tashiro A; Fujiyama S; Nagahiro T; Takano H; Araki K; Sagara K; Sato T
    Kaku Igaku; 1980 Dec; 17(10):1249-56. PubMed ID: 6162980
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
    Haglund C; Roberts PJ; Jalanko H; Kuusela P
    Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers.
    Motoo Y; Satomura Y; Kawakami H; Watanabe H; Ohta H; Okai T; Sawabu N
    Oncology; 1990; 47(6):456-62. PubMed ID: 2243663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei])].
    Sugano K; Kawai T; Ishii M; Koyama H; Kitajima M; Kasumi F; Demura R; Nakayama T; Okabe H; Mori S
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1255-62. PubMed ID: 7913313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on secretory component in digestive disease. III. Levels of serum secretory component in digestive disease.
    Kunishi K
    Gastroenterol Jpn; 1980; 15(5):444-7. PubMed ID: 7439618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary gonadotropin peptide in patients with cancer of digestive organs.
    Motoo Y; Watanabe H; Yamaguchi Y; Mouri I; Fujii T; Yamakawa O; Satomura Y; Okai T; Sawabu N
    Anticancer Res; 1996; 16(4A):2041-8. PubMed ID: 8712740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.